Source-grounded facts extracted from BIOTRICITY INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BIOTRICITY INC. issued an aggregate of 1,957,297 shares of newly created Series C Preferred Stock of preferred stock to holders of Exchange Securities (Exchange Holders) for exchange of Exchange Securities consisting of common stock, options, and warrants.
“the Exchange Holders exchanged their Exchange Securities for an aggregate of 1,957,297 shares of newly created Series C Preferred Stock of the Company (on the basis of ten Exchange Securities for one share of Series C Preferred Stock).”
BIOTRICITY INC. entered into Exchange Agreement with Holders of Exchange Securities valued at Exchange of 14,144,325 common shares, options for 3,992,427 shares, and warrants for 1,436,216 share (effective 2026-05-01).
“On May 1, 2026, Biotricity Inc. (the “Company”) entered into exchange agreements with holders (the “Exchange Holders”) of an aggregate of 14,144,325 shares of the Company’s common stock (the “Exchange Shares”), options (the “Exchange Options”) to purchase 3,992,427 shares of common stock of the Company, and warrants (the “Exchange Warrants,” and together with the Exchange Shares and the Exchange Options, the “Exchange Securities”) to purchase 1,436,216 shares of common stock of the Company.”
BIOTRICITY INC. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).
“May 1, 2024, Biotricity Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) stating that it is not in compliance with the Nasdaq Listing Rule 5620(a) (the “Rule”) requiring that the Company hold an annual meeting of stockholders within 12 months of the end of its fiscal year. The notification received has no immediate effect on the Company’s continued listing on the Nasdaq Capital Market, subject to its compliance with the other continued listing requirements. In the letter dated May 1, 2024, Nasdaq notified the Company that this serves as an additional basis for del”
BIOTRICITY INC. received a nasdaq extension granted notice regarding market value.
“April 23, 2024, Nasdaq notified the Company that the Panel granted its request to continue its listing on Nasdaq, subject to the Company meeting certain milestones including an increase in its outstanding shares of common stock through the issuance of shares of stock in certain stock offerings and upon the conversion of certain convertible securities, the receipt of shareholder approval of certain actions and on or before July 29, 2024, the Company regaining compliance with all applicable requirements for continued listing on The Nasdaq Capital Market.”
BIOTRICITY INC.: Amended Certificate of Designations for Series B Convertible Preferred Stock to remove voting rights on an as-converted basis, making the shares non-voting except as required by law (effective 2024-04-01).
“The Amended Certificate of Designations removes the provision in the original certificate of designations for the Series B Convertible Preferred Stock filed on September 19, 2023 that provided the holders of the Series B Preferred Stock with the right to vote on an as-converted basis with the Company’s common stock, subject to the beneficial ownership limitation set forth in the Certificate of Designations. The Amended Certificate of Designations provides that except as required by law, the Series B Preferred Stock is non-voting.”
BIOTRICITY INC. shareholders approved Approval of Amended Certificate of Designations for Series B Preferred Stock at the 2024-04-01 meeting.
“the holder of the outstanding Seies B Preferred Stock approved the Amended Certificate of Designations via written consent”
BIOTRICITY INC. entered into Purchase Agreement with an institutional investor (effective 2024-03-25).
“On March 25, 2024, Biotricity Inc. (the “Company”) entered into a security purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”) for the issuance and sale, in a private placement offering (the “Private Placement”), of 110 shares of the Company’s Series B Convertible Preferred Stock, $0.001 par value (the “Series B Preferred Stock”), at a purchase price of $9,090.91 per share of Series B Convertible Preferred Stock, for gross proceeds of $1,000,000.”
BIOTRICITY INC. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
“January 30, 2024, the Company received a delisting determination letter (the “Letter”) from the Staff advising the Company that the Staff had determined that the Company did not regain compliance with the MVLS Requirement by the Compliance Date because the Company’s MVLS did not close at or above $35 million for a minimum of 10 consecutive business days prior to the Compliance Date. As a result, unless the Company requests an appeal of the Staff’s determination, trading of the Company’s common stock on the Nasdaq Capital Market will be suspended at the opening of business on February 8, 2024”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.